ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Vivos Inc (QB)

Vivos Inc (QB) (RDGL)

0.127
0.01248
(10.90%)
Cerrado 04 Febrero 3:00PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
0.127
Postura de Compra
0.1251
Postura de Venta
0.128
Volume Operado de la Acción
2,027,818
0.1201 Rango del Día 0.1399
0.049 Rango de 52 semanas 0.255
Capitalización de Mercado [m]
Precio Anterior
0.11452
Precio de Apertura
0.132
Última hora de negociación
Volumen financiero
US$ 265,283
Precio Promedio Ponderado
0.130822
Volumen promedio (3 m)
1,295,123
Acciones en circulación
417,592,703
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-18.84
Beneficio por acción (BPA)
-0.01
turnover
20k
Beneficio neto
-2.9M

Acerca de Vivos Inc (QB)

Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially avai... Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially available for animal therapy and can deliver very high doses to solid tumors with a single same day therapy. Pre-clinical testing is in progress to generate key data for an Investigational Devise Exemption to the FDA to begin human clinical trials. Mostrar más

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Vivos Inc (QB) is listed in the Surgical,med Instr,apparatus sector of the OTCMarkets with ticker RDGL. The last closing price for Vivos (QB) was US$0.11. Over the last year, Vivos (QB) shares have traded in a share price range of US$ 0.049 to US$ 0.255.

Vivos (QB) currently has 417,592,703 shares in issue. The market capitalisation of Vivos (QB) is US$47.82 million. Vivos (QB) has a price to earnings ratio (PE ratio) of -18.84.

RDGL Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.0010.7936507936510.1260.13990.1117177020.11887671CS
4-0.023-15.33333333330.150.15710.11111256460.13345863CS
120.01715.45454545450.110.160.061112951230.11283408CS
260.03639.56043956040.0910.1840.061111768810.12184488CS
520.069118.9655172410.0580.2550.04913441270.13620733CS
1560.059688.42729970330.06740.2550.047756940.10563178CS
2600.097323.3333333330.030.310.013510837130.10196902CS

RDGL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Vivos (QB)?
El precio actual de las acciones de Vivos (QB) es US$ 0.127
¿Cuántas acciones de Vivos (QB) están en circulación?
Vivos (QB) tiene 417,592,703 acciones en circulación
¿Cuál es la capitalización de mercado de Vivos (QB)?
La capitalización de mercado de Vivos (QB) es USD 47.82M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Vivos (QB)?
Vivos (QB) ha negociado en un rango de US$ 0.049 a US$ 0.255 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Vivos (QB)?
El ratio precio/beneficio de Vivos (QB) es -18.84
¿Cuál es la moneda de reporte de Vivos (QB)?
Vivos (QB) presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Vivos (QB)?
El último ingresos anual de Vivos (QB) es USD 20k
¿Cuál es el último beneficio anual de Vivos (QB)?
El último beneficio anual de Vivos (QB) es USD -2.9M
¿Cuál es la dirección registrada de Vivos (QB)?
La dirección registrada de Vivos (QB) es CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Vivos (QB)?
La dirección del sitio web de Vivos (QB) es www.radiogel.com
¿En qué sector industrial opera Vivos (QB)?
Vivos (QB) opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ELIQQElectriq Power Holdings Inc (CE)
US$ 0.20
(199,900.00%)
100
THMOThermoGenesis Holdings Inc (CE)
US$ 0.0007
(69,900.00%)
462
ALKMAlkame Holdings Inc (CE)
US$ 0.0001
(9,900.00%)
100k
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(9,900.00%)
340.21M
PSRUValiant Eagle Inc (PK)
US$ 0.0001
(9,900.00%)
18.05M
TTMZFDatable Technology Corporation (CE)
US$ 0.000001
(-100.00%)
1,000
VRVRVirtual Interactive Technologies Corporation (CE)
US$ 0.0005
(-99.87%)
2.4k
PKLBFPerk Labs Inc (CE)
US$ 0.000001
(-99.67%)
9k
CLVRClever Leaves Holdings Inc (CE)
US$ 0.0001
(-99.60%)
1.6k
EFTReFFECTOR Therapeutics Inc (CE)
US$ 0.000001
(-99.50%)
110
RONNRonn Motor Group Inc (PK)
US$ 0.0003
(50.00%)
360.82M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(9,900.00%)
340.21M
PHILPHI Group Inc (PK)
US$ 0.0003
(50.00%)
260.49M
HMBLHUMBL Inc (PK)
US$ 0.0007
(7.69%)
226.69M
TKMOTekumo Inc (PK)
US$ 0.0003
(-14.29%)
185.82M

RDGL Discussion

Ver más
Grig81 Grig81 50 minutos hace
Omg. You are so boring and so predictable. We all get it....you're not a fan of the company. You believe MK is incompetent. How about you save yourself hours upon hours of your life and just stop posting. Just assume we all know what your opinion is. Go out... get some fresh air. Make friends. Make memories. 
👍️0
Bigfootbud Bigfootbud 1 hora hace
$RDGL!!! :) :) :) Helping Humans. 🤍
👍️0
WALLnut WALLnut 2 horas hace
Your assumption about the worst vs. best patient outcome is speculation, not fact. While it's possible MK highlighted the most promising case first, that doesn’t mean the other four patients fared worse—or that the treatment failed.

1. Occam’s Razor Works Both Ways

You assume MK picked the best patient to “crow about.” But just as easily, he may have chosen the first available 30-day scan or the most representative case.

If the treatment were failing across the board, he wouldn’t highlight any patient at all, as that would backfire.

The simplest explanation? Vivos is following standard clinical reporting—early data points first, with more to come.


2. You’re Ignoring the Other Possibilities

If Vivos were hiding bad results, they wouldn’t be running a transparent clinical trial with regulatory oversight.

Maybe the other patients were treated later and haven’t reached the 30-day scan window yet.

Maybe they had similar outcomes, and MK simply reported the first available case.


3. The Real Test Comes With More Data

We can argue about assumptions all day, but assumptions aren’t data.



Instead of cherry-picking assumptions, let’s wait for the full dataset. That’s how science works—not by making conclusions based on incomplete evidence."


RDGL
👍️0
Roofus Roofus 2 horas hace
Yep, it was a 5 star PR
👍️0
doccjc doccjc 4 horas hace
Some Key Takeaways from today's PR :
1) Safety Confirmed : No reported adverse events in the first 5 patients.

2) Early Efficacy Signs: PET scans show significant tumor reduction and decrease in metastatic activity..

3) Trial Expansion Planned : Proposal to increase from 30 to 50 patients for broader data collection.

4) New Technology : Introduction of a Deep Needle CT guided injection device for targeting deeper tumors like lung and pancreatic cancer.

That was quite the PR today.
👍️0
WALLnut WALLnut 4 horas hace
You're oversimplifying cancer metabolism and misrepresenting how treatment response is evaluated. Yes, active cancer cells metabolize glucose, but PET scans alone do not distinguish between live cancer cells, inflammation, or post-radiation immune activity.

1. PET Uptake ? Proof of Treatment Failure

Radiation doesn’t kill all cancer cells instantly. Some die immediately, while others undergo delayed apoptosis over weeks to months.

PET scans can show false positives due to radiation-induced inflammation and immune responses—common after Y-90 therapies.

This is why standard oncology protocols use multiple follow-up scans (60, 90, 180 days) before declaring success or failure.


2. MK "Jumping the Gun"? Not Necessarily

Reporting a single 30-day PET scan does not mean he’s making final success claims—it’s an early data point.

The FDA requires step-by-step trial reporting, including preliminary results.

Declaring MK "grossly incompetent" ignores the reality of regulatory hurdles, clinical trial design, and multi-month patient tracking.


3. What Comes Next Matters More

If subsequent PET scans show continued tumor shrinkage, then your argument collapses.

If the tumor still shows metabolic activity at 90+ days without further shrinkage, then additional data is needed to refine dosing or protocol.


Bottom line: It’s premature to call this a failure OR a success at 30 days. The proper scientific approach is to wait for multi-month follow-up results before making definitive claims. Let’s base conclusions on complete data, not just assumptions."

RDGL
👍️ 2
doccjc doccjc 4 horas hace
"While the trial’s primary objective is to establish safety, these early signs of efficacy are highly encouraging ".
We are in Phase 1. That is the phase to determine safety. 100 % safety results.
The trial is expanding to 50 patients.
Quite the reach to state that a trial has failed in Phase 1 because it has not exhibited 100% safety. AND 100% efficacy.
👍️0
SC8 SC8 4 horas hace
Sure seems if a cancer cell continues to ferment glucose, as is typical for cancer cells vs. normal cells, hence how F18 labeled glucose lights up cancer but not normal cells for PET scan, that cancer is alive and well. On the other hand, even if I stipulate to all you say about more time is needed to know, that only confirms MK has again jumped the gun with unsubstantiated product performance and safety claims. Either way, MK is again proven a gross incompetent getting Radiogel to market.

As far as how the other 4 patients fared, I'm assuming the one MK chose to crow about had the most positive outcome so far. That is a very safe assumption. Would he crow about the worse outcome and not bother mentioning the better outcomes? That seems very unlikely. Always go with Occam. He's hardly ever wrong.
👍️0
WALLnut WALLnut 5 horas hace
Wrong.

"Your understanding of tumor response to radiation, especially Yttrium-90 (Y-90) brachytherapy, is incomplete. While it's true that dead tumors don’t uptake F-18 glucose, your conclusion that the treatment failed based solely on a 30-day PET scan is premature and ignores how radiation therapy works over time.

1. Radiation-Induced Tumor Death Takes Time

Y-90 delivers high-dose beta radiation locally, and while some cells die immediately, others undergo delayed apoptosis (programmed cell death) that unfolds over weeks to months.

Clinical studies on Y-90-based therapies (like TheraSphere and SIR-Spheres) show that tumors can continue shrinking for 3-6 months post-treatment, even after Y-90 has fully decayed.



2. 30-Day PET Scan Alone Does Not Confirm Failure

PET scans show glucose metabolism, not necessarily viable cancer cells. Post-radiation inflammation, immune cell activity, and even necrotic tissue can sometimes cause false-positive uptake in the early months.

This is why oncologists don’t declare treatment failure at 30 days—they track progression over multiple scans (60, 90, and even 180 days).



3. No Evidence That “Other Patients Fared Worse”

You're making an unsupported assumption about the other four patients. One report does not equal overall failure, and we don’t have final trial data yet.

The full results, including longer follow-up scans and biopsies, will determine whether the treatment is working.




Conclusion: Declaring failure at 30 days ignores well-established radiation oncology principles. The correct way to assess RadioGel’s effectiveness is long-term tumor response, not an isolated PET scan. Let’s wait for additional data before making sweeping claims."

RDGL
👍️ 2
doccjc doccjc 5 horas hace
While the trial’s primary objective is to establish safety, these early signs of efficacy are highly encouraging.




👍️0
doccjc doccjc 5 horas hace
After completing the detailed assessment of the available data from the patients, the results will be presented to the Ethics Committee. The lead investigator intends to request authority to increase the study from 30 patients to 50 patients.
👍️0
doccjc doccjc 5 horas hace
Richland, WA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision Radionuclide TherapyTM by satisfying the criteria in the Clinical Study Plan, including confirmation via PET imaging that the Y-90 remained at the point of injection and no adverse events reported by any of the initial five patients since the initial treatment date.
👍️0
SC8 SC8 5 horas hace
Wrong. PET scan showing cancer uptake of F18 labeled glucose lighting up tumor 30 days post treatment is gold standard proof the cancer survived the treatment. Dead tumors don't metabolize anything and don't uptake glucose or F18 labeled glucose. There's no Y90 left now to continue killing the remaining tumor. The surviving portion will grow and spread. The treatment failed at least for the one patient MK chose to report about. Safe to assume the others fared worse.
👍️0
WALLnut WALLnut 5 horas hace
Patient increase speaks volumes for Radiogels first in-patient results and potential.

Now If Radiogel didn't kill the tumor like Skate said it didn't, would a Lead investigator push for extra patient's to treat in a phase II trial? or would they hold off and revaluate Radiogel disposition? Hmmm ...Boy this is a tuffy.



RDGL
👍️0
BBANBOB BBANBOB 6 horas hace
Been here several yrs and aint going nowhere and have just added lots more in the last 6 months to a yr
👍️0
mikepgator mikepgator 8 horas hace
Yes, very interesting that the investigator didn’t wait to see the results of the 30 before expanding to 50, all he needed to see was the results at only 5 after only 30 days.
👍️ 3
WALLnut WALLnut 8 horas hace
Lead investigator even looking to increase patients from 30 to 50 due to the 5 patients bad ass positive results.



RDGL
👍️ 2
stocup stocup 8 horas hace
Soon as the 50-80% flippers are done we’ll move up.
👍️0
BBANBOB BBANBOB 8 horas hace
Rdgl did pretty good today and held 10% gains, I'll take 10% any day on any stock.
Still say 15-18 by Friday maybe even more
👍️ 1
chereb19 chereb19 8 horas hace
Perfect dose perfect result. Just ask the lead investigator
👍️ 1
chereb19 chereb19 8 horas hace
Do you know what a phase 1 trial is? The lead investigator loved the results
👍️0
WALLnut WALLnut 9 horas hace
Tumors are dead, just like your job here. Tumors shrunk 80% in 30 days. In the next 15 days tumor will have shrunk to 95% and in at total of 6 months, tumor will no longer exist in the 5 patients.

Shrunk and shriveled = Dead.



RDGL
👍️0
mikepgator mikepgator 9 horas hace
Lol you’re too funny, just months ago you were claiming Radiogel would never make it to human trials, and now you’re claiming that the dosage for the very first human trial wasn’t precise enough.
👍️0
SC8 SC8 9 horas hace
So they screwed up and gave too low a dose, but somehow that confirms safety at proper dose? Again, the delusions with MK's sycophants have no bounds.
👍️0
SC8 SC8 9 horas hace
So Radiogel does nothing for 5 doomed patients, doesn't even kill the treated tumors, but somehow that confirms Radiogel safety? The delusions here know no bounds.
👍️0
doccjc doccjc 9 horas hace
Even at this lower dose , they got 80 % tumor size reduction and 80% less metastatic activity . Imagine when they play with the doses on these next studies.  And let's not forget we have more indications with the 50 patient studies utilizing the deep needle CT technique 
👍️ 3 💯 1
rickstereo3333 rickstereo3333 9 horas hace
Agreed......IMO Vivos should be able to tinker with the amount of Radiogel that's infected into the tumor and/or modify the concentration of Y90 in the gel in order to fully destroy the cancerous growth.

This is just a little snippet out of the host of options open to them.
👍️ 1
CatfishHunter CatfishHunter 9 horas hace
He already knows that. Why do you think he refuses to answer the question about why MK chose cancer of lymph nodes as initial trial. 
👍️0
AtlasQ AtlasQ 9 horas hace
Great day.

Now we wait.
👍️0
rickstereo3333 rickstereo3333 9 horas hace
The benchmark of the trial is SAFETY.....more reading and less scamming sceeate!!!

(Richland, WA – February 4, 2025) – Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision Radionuclide TherapyTM by satisfying the criteria in the Clinical Study Plan, including confirmation via PET imaging that the Y-90 remained at the point of injection and no adverse reported by any of the initial five patients since the initial treatment date.

Do keep yapping about Punts while Vivos keeps scoring Touchdowns. lololsss
👍️0
CatfishHunter CatfishHunter 10 horas hace
False statement. We all know that. The radiogel has been proven to be successful with pets and animals removing the tumor with no reoccurrence. The 90 day report on the five patients will just provide further indication of that. Fact are facts. Another swing and a miss.
👍️0
doccjc doccjc 10 horas hace
An 80% reduction in tumor size in just 30 days  is very promising , especially for a localized cancerous node near the trachea where other treatments can have severe side effects .  The doses will be altered in future studies. Ignore the noise . 
👍️0
chereb19 chereb19 10 horas hace
That's not how it works.

Radiogel has killed the tumor and it's on its way out
👍️0
chereb19 chereb19 10 horas hace
That's not how it works. You got it wrong again. The tumor is going and the Indian singer is happy
👍️0
doccjc doccjc 10 horas hace


👍️0
doccjc doccjc 10 horas hace
First trial results were to determine safety . 100 % pass 
👍️ 3 💯 1
SC8 SC8 10 horas hace
MK's own update says otherwise. Tumor is still alive metabolizing glucose 30 days post treatment, long after the 10 days or so there's enough Y90 to kill tumor. Tumor survived treatment. Sadly that was apparently the best result. Radiogel failed.
👍️0
CatfishHunter CatfishHunter 10 horas hace
VIVO wins. You lose. Trying to spin a false narrative like CNN won't help. 
👍️ 1 💯 1
SC8 SC8 10 horas hace
Sorry, MK reported this was 30 days post treatment. There's no Y90 left to continue killing tumor. Tumor survived the treatment. And this was his cherry picked best result. Sad.
👍️0
rickstereo3333 rickstereo3333 10 horas hace
The more you flail around on here the more you expose yourself Muppet. lololsss
👍️ 1 💯 1
rickstereo3333 rickstereo3333 10 horas hace
Apparently the Muppet sceeate believes that a trial's initial dosage is always 100% effective on the first attempt.....as a matter of fact, it virtually never does.

Not to mention, once again, that the site chosen ie lymph nodes, had limited to no other treatment option available thus making the 80% reduction in one patient even more incredible.

The scamming clown's narrative is not just ludicrous, its totally idiotic.
👍️ 2 💯 1 😜 1
CatfishHunter CatfishHunter 10 horas hace
Always easy to ignore a question you're afraid to answer.  
👍️0
chereb19 chereb19 10 horas hace
The lead investigator likes the results. Lol

You must try harder
👍️ 1
doccjc doccjc 10 horas hace


👍 1
chereb19 chereb19 10 horas hace
Dosimetry looks perfect.
👍️ 1
chereb19 chereb19 10 horas hace
What a whopper of a lie. The tumor is dying. Radiogel killed it
👍️ 1
doccjc doccjc 10 horas hace


👍️0
chereb19 chereb19 10 horas hace
You don't really do science do you. The tumor is disappearing
👍️0
chereb19 chereb19 10 horas hace
Great success again..the tumor is going away nicely as expected
👍️ 1
chereb19 chereb19 10 horas hace
The tumor is virtually non-exsitent after 30 days. Like all the other tumors it will be gone.

I bet the Indian singer is shouting from the roof tops
👍️0